MoonLake Immunotherapeutics (MLTX)
MLTX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$10.41
-2.53% on the day
Market cap
$886.0M
Small cap
Revenue
Not reported in SEC XBRL data
Net income
Not reported in SEC XBRL data
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | MLTX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2020 |
| SEC CIK | 0001821586 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | E9 |
Financials
Not reported in SEC XBRL data.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document REGISTRATION STATEMENT | S-3ASR | 2026-08-10 |
| Latest annual report | 10-K | 2026-02-25 |
| Latest quarterly / interim | 10-Q | 2026-08-10 |
| Latest current report CURRENT REPORT | 8-K | 2026-09-30 |
| Latest proxy | DEFA14A | 2026-04-21 |
Source: SEC EDGAR submissions feed, 329 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -5.3% |
| 1 month | -16.4% |
| 3 months | -46.4% |
| Year to date | -22.6% |
| 1 year | -4.4% |
| From 52-week high | -54.0% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| RIGL | Rigel Pharmaceuticals Inc. | $47.14 | -3.42% | $880.6M |
| KURA | Kura Oncology Inc. | $9.83 | -5.43% | $874.5M |
| ANRO | Alto Neuroscience Inc. | $22.09 | -8.53% | $866.9M |
| SPTX | Seaport Therapeutics Inc. | $16.08 | -6.24% | $860.8M |
| CYRX | CryoPort Inc. | $16.95 | +0.65% | $858.5M |
| JBIO | Jade Biosciences Inc. | $13.42 | -4.14% | $853.5M |
| ALMS | Alumis Inc. | $6.56 | -7.08% | $849.1M |
| AKTS | Aktis Oncology Inc. | $16.64 | -4.04% | $925.5M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier